Investigating stage-specific metabolic alterations in colorectal cancer through urine metabolomics.

IF 3.3 3区医学 Q2 ENDOCRINOLOGY & METABOLISM

Metabolomics Pub Date : 2025-10-22 DOI:10.1007/s11306-025-02344-x

Feng Qi, Yulin Sun, Jiaqi Liu, Xiaoyan Liu, Haidan Sun, Zhengguang Guo, Binbin Zhang, Jiameng Sun, Aiwei Wang, Hezhen Lu, Fei Xue, Tingmiao Li, Xin Qi, Xiaohang Zhao, Wei Sun

{"title":"Investigating stage-specific metabolic alterations in colorectal cancer through urine metabolomics.","authors":"Feng Qi, Yulin Sun, Jiaqi Liu, Xiaoyan Liu, Haidan Sun, Zhengguang Guo, Binbin Zhang, Jiameng Sun, Aiwei Wang, Hezhen Lu, Fei Xue, Tingmiao Li, Xin Qi, Xiaohang Zhao, Wei Sun","doi":"10.1007/s11306-025-02344-x","DOIUrl":null,"url":null,"abstract":"Background: Colorectal cancer (CRC) ranks as the third most prevalent malignancy globally, presenting a formidable early diagnostic challenge. An effective biomarker with high sensitivity and specificity can help diagnose CRC and improve the chances of successful treatment.Methods: 100 healthy controls and 95 CRC patients (25 Stage 0/I, 30 stage II and 40 stage III based on Clinical stages) were recruited. Subsequently, 195 urine samples were subjected to UPLC-MS analysis. Comparative analysis was employed to elucidate noteworthy metabolic variances, and pathway analysis was conducted to unveil perturbed metabolic functions. Ultimately, metabolic panels for CRC diagnosis were constructed.Result: A total of 82 metabolites exhibited statistical significance between CRC patients and healthy controls. Moreover, pathway analysis revealed that they were associated with Steroid hormone biosynthesis, Nitrogen metabolism, and D-Glutamine and D-glutamate metabolism. A composite panel consisting of Retinol, L-β-aspartyl-L-glycine, and 21-Deoxycortisol showed AUCs of 0.933/0.93 in the discovery/validation group. The panel also showed commendable efficacy across different CRC stages when these stages were compared with the healthy group,with an AUC of 0.918 for stages 0/I, 0.862 for stage II, and 0.845 for stage III.Conclusions: Urine metabolome could distinguish CRC from healthy controls and reflect the changes in different stages of CRC. Potential biomarkers might be developed by targeted metabolomic analysis.","PeriodicalId":18506,"journal":{"name":"Metabolomics","volume":"21 6","pages":"152"},"PeriodicalIF":3.3000,"publicationDate":"2025-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Metabolomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11306-025-02344-x","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Colorectal cancer (CRC) ranks as the third most prevalent malignancy globally, presenting a formidable early diagnostic challenge. An effective biomarker with high sensitivity and specificity can help diagnose CRC and improve the chances of successful treatment.

Methods: 100 healthy controls and 95 CRC patients (25 Stage 0/I, 30 stage II and 40 stage III based on Clinical stages) were recruited. Subsequently, 195 urine samples were subjected to UPLC-MS analysis. Comparative analysis was employed to elucidate noteworthy metabolic variances, and pathway analysis was conducted to unveil perturbed metabolic functions. Ultimately, metabolic panels for CRC diagnosis were constructed.

Result: A total of 82 metabolites exhibited statistical significance between CRC patients and healthy controls. Moreover, pathway analysis revealed that they were associated with Steroid hormone biosynthesis, Nitrogen metabolism, and D-Glutamine and D-glutamate metabolism. A composite panel consisting of Retinol, L-β-aspartyl-L-glycine, and 21-Deoxycortisol showed AUCs of 0.933/0.93 in the discovery/validation group. The panel also showed commendable efficacy across different CRC stages when these stages were compared with the healthy group,with an AUC of 0.918 for stages 0/I, 0.862 for stage II, and 0.845 for stage III.

Conclusions: Urine metabolome could distinguish CRC from healthy controls and reflect the changes in different stages of CRC. Potential biomarkers might be developed by targeted metabolomic analysis.

查看原文本刊更多论文

通过尿液代谢组学研究结直肠癌分期特异性代谢改变。

背景：结直肠癌（CRC）是全球第三大最常见的恶性肿瘤，提出了一个巨大的早期诊断挑战。一种具有高灵敏度和特异性的有效生物标志物可以帮助诊断结直肠癌并提高成功治疗的机会。方法：招募健康对照100例，CRC患者95例（0/I期25例，II期30例，III期40例）。随后，195份尿样进行UPLC-MS分析。通过比较分析阐明值得注意的代谢差异，通过途径分析揭示代谢功能紊乱。最后，构建了用于结直肠癌诊断的代谢组。结果：结直肠癌患者与健康对照组之间共有82项代谢物具有统计学意义。此外，通路分析显示它们与类固醇激素的生物合成、氮代谢、d -谷氨酰胺和d -谷氨酸代谢有关。由视黄醇、L-β-天冬氨酸-L-甘氨酸和21-脱氧皮质醇组成的复合面板在发现/验证组的auc为0.933/0.93。当这些阶段与健康组比较时，该小组在不同的CRC阶段也显示出值得称赞的疗效，0/I期的AUC为0.918，II期为0.862，III期为0.845。结论：尿代谢组可以区分结直肠癌与健康对照，反映结直肠癌不同阶段的变化。有针对性的代谢组学分析可能会开发出潜在的生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Metabolomics 医学-内分泌学与代谢

CiteScore

6.60

自引率

2.80%

发文量

审稿时长

2 months

期刊介绍： Metabolomics publishes current research regarding the development of technology platforms for metabolomics. This includes, but is not limited to: metabolomic applications within man, including pre-clinical and clinical pharmacometabolomics for precision medicine metabolic profiling and fingerprinting metabolite target analysis metabolomic applications within animals, plants and microbes transcriptomics and proteomics in systems biology Metabolomics is an indispensable platform for researchers using new post-genomics approaches, to discover networks and interactions between metabolites, pharmaceuticals, SNPs, proteins and more. Its articles go beyond the genome and metabolome, by including original clinical study material together with big data from new emerging technologies.